Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Fernando López-Campos, Estefanía Linares-Espinós, Xavier Maldonado Pijoan, Gemma Sancho Pardo, Todd Mathew Morgan, Claudio Martínez-Ballesteros, Juan Martínez-Salamanca & Felipe Couñago. (2020) Genetic testing for the clinician in prostate cancer. Expert Review of Molecular Diagnostics 20:9, pages 933-946.
Read now
Read now
Timothy N. Clinton, Aditya Bagrodia, Yair Lotan, Vitaly Margulis, Ganesh V. Raj & Solomon L. Woldu. (2017) Tissue-based biomarkers in prostate cancer. Expert Review of Precision Medicine and Drug Development 2:5, pages 249-260.
Read now
Read now
Robert E. Reiter. (2016) Risk stratification of prostate cancer 2016. Scandinavian Journal of Clinical and Laboratory Investigation 76:sup245, pages S54-S59.
Read now
Read now
Lisa Murphy, Maria Prencipe, William M Gallagher & R William Watson. (2015) Commercialized biomarkers: new horizons in prostate cancer diagnostics. Expert Review of Molecular Diagnostics 15:4, pages 491-503.
Read now
Read now
Articles from other publishers (65)
Akshay Sood, Amar U. Kishan, Christopher P. Evans, Felix Y. Feng, Todd M. Morgan, Declan G. Murphy, Anwar R. Padhani, Peter Pinto, Henk G. Van der Poel, Derya Tilki, Alberto Briganti & Firas Abdollah. (2023) The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. European Urology Oncology.
Crossref
Crossref
Sisi Qin, Huanyao Gao, Wootae Kim, Huan Zhang, Yayun Gu, Krishna R. Kalari, Jason P. Sinnwell, Jodi A. Scholz, Fang Xie, Ping Yin, Jia Yu, Bo Qin, Yongxian Zhuang, Lixuan Wei, Winston Tan, Alan H. Bryce, Richard M. Weinshilboum & Liewei Wang. (2022) Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer. Clinical Pharmacology & Therapeutics 111:6, pages 1296-1306.
Crossref
Crossref
Vanessa Kuhl, Wyatt Clegg, Stephanie Meek, Lauren Lenz, Darl D FlakeIIII, Tracy Ronan, Max Kornilov, Deborah Horsch, Marsel Scheer, Daniel Farber, Hillary Zalaznick, Olivier Cussenot, Eva Compérat, Geraldine Cancel-Tassin, Peter J Wild, Felix KH Chun, Philipp Mandel, Farid Moinfar, Todd Cohen, Sylvette Delee, Ralf Kronenwett & Jennifer Doedt. (2022) Development and validation of a cell cycle progression signature for decentralized testing of men with prostate cancer. Biomarkers in Medicine 16:6, pages 449-459.
Crossref
Crossref
Mahnoosh Rahimi & Sheldon Greenfield. (2022) A Systematic Review of Decipher Genomic Classifier Risk Scores for
Prostate Cancer in African-Americans. Current Pharmacogenomics and Personalized Medicine 19:1, pages 7-20.
Crossref
Crossref
Ali Al-Fatlawi, Nazia Afrin, Cigdem Ozen, Negin Malekian & Michael Schroeder. (2022) NetRank Recovers Known Cancer Hallmark Genes as Universal Biomarker Signature for Cancer Outcome Prediction. Frontiers in Bioinformatics 2.
Crossref
Crossref
Mark W. Farha & Simpa S. Salami. (2022) Biomarkers for prostate cancer detection and risk stratification. Therapeutic Advances in Urology 14, pages 175628722211039.
Crossref
Crossref
Adam S. Feldman, Vinata Lokeshwar & Daniel W. Lin. (2021) A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urologic Oncology: Seminars and Original Investigations 39:9, pages 602-617.
Crossref
Crossref
James Meehan, Mark Gray, Carlos Martínez-Pérez, Charlene Kay, Duncan McLaren & Arran K. Turnbull. (2021) Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine. Journal of Personalized Medicine 11:7, pages 664.
Crossref
Crossref
Gary Gustavsen, Kelsey Taylor, Doria Cole, Laura Gullet & Nicolas Lewine. (2020) Health economic impact of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Future Oncology 16:36, pages 3061-3074.
Crossref
Crossref
Claire Tonry, Stephen Finn, John Armstrong & Stephen R. Pennington. (2020) Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. Clinical Proteomics 17:1.
Crossref
Crossref
Rodrigo Delgadillo, John C. Ford, Matthew C. Abramowitz, Alan Dal Pra, Alan Pollack & Radka Stoyanova. (2020) The role of radiomics in prostate cancer radiotherapy. Strahlentherapie und Onkologie 196:10, pages 900-912.
Crossref
Crossref
Majid Assadi, Narges Jokar, Mojtaba Ghasemi, Iraj Nabipour, Ali Gholamrezanezhad & Hojjat Ahmadzadehfar. (2020) Precision Medicine Approach in Prostate Cancer. Current Pharmaceutical Design 26:31, pages 3783-3798.
Crossref
Crossref
Scott E. Eggener, R. Bryan Rumble, Andrew J. Armstrong, Todd M. Morgan, Tony Crispino, Philip Cornford, Theodorus van der Kwast, David J. Grignon, Alex J. Rai, Neeraj Agarwal, Eric A. Klein, Robert B. Den & Himisha Beltran. (2020) Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology 38:13, pages 1474-1494.
Crossref
Crossref
Anmar M. Nassir. (2020) A piece in prostate cancer puzzle: Future perspective of novel molecular signatures. Saudi Journal of Biological Sciences 27:4, pages 1148-1154.
Crossref
Crossref
Luke Pardy, Rayna Rosati, Claire Soave, Yanfang Huang, Seongho Kim & Manohar Ratnam. (2019) The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer. The Prostate 80:2, pages 198-208.
Crossref
Crossref
D. S. Mikhaylenko, S. A. Sergienko, B. Ya. Alekseev, A. D. Kaprin & M. V. Nemtsova. (2020) Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer. Cancer Urology 15:4, pages 18-29.
Crossref
Crossref
Noam David Fine, Fred LaPolla, Matthew Epstein, Stacy Loeb & Hasan Dani. (2019) Genomic classifiers for treatment selection in newly diagnosed prostate cancer. BJU International 124:4, pages 578-586.
Crossref
Crossref
Štěpán Veselý. (2019) Current clinical utility of prostate cancer markers. Onkologie 13:2, pages 78-82.
Crossref
Crossref
Daniel E. Oliver, Homan Mohammadi, Nicholas Figura, Jessica M. Frakes, Kosj Yamoah, Bradford A. Perez, Evan J. Wuthrick, Arash O. Naghavi, Jimmy J. Caudell, Louis B. Harrison, Javier F. Torres-Roca & Kamran A. Ahmed. (2019) Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology 29:2, pages 111-125.
Crossref
Crossref
Derya Tilki, Thenappan Chandrasekar, Alexander Kretschmer & Felix K. Chun. 2019. Urologic Oncology. Urologic Oncology
109
124
.
Wesley M Hiser, Valentina Sangiorgio, Enrico Bollito, Ashwini Esnakula, Michael Feely & Sara M Falzarano. (2018) Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. Future Oncology 14:29, pages 3073-3083.
Crossref
Crossref
Dimitry A. Chistiakov, Veronika A. Myasoedova, Andrey V. Grechko, Alexandra A. Melnichenko & Alexander N. Orekhov. (2018) New biomarkers for diagnosis and prognosis of localized prostate cancer. Seminars in Cancer Biology 52, pages 9-16.
Crossref
Crossref
Jane Kim Nguyen & Cristina Magi-Galluzzi. (2018) Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. Advances in Anatomic Pathology 25:5, pages 293-303.
Crossref
Crossref
A. Jalón Monzón, M. Alvarez Múgica, M. Jalón Monzón & S. Escaf Barmadah. (2018) Qué debe saber el médico de primaria sobre los nuevos marcadores en el cáncer de próstata. Medicina de Familia. SEMERGEN 44:6, pages 430-438.
Crossref
Crossref
Marc Zanaty, Khaled Ajib, Kevin Zorn & Assaad El-Hakim. (2018) Functional outcomes of robot-assisted radical prostatectomy in patients eligible for active surveillance. World Journal of Urology 36:9, pages 1391-1397.
Crossref
Crossref
Arie Carneiro, Paulo Priante Kayano, Álan Roger Gomes Barbosa, Marcelo Langer Wroclawski, Carolina Ko Chen, Giulio Costa Cavlini, Guilherme Jose Reche, Rafael Sanchez-Salas, Marcos Tobias-Machado, Adam G Sowalsky & Bianca Bianco. (2018) Are localized prostate cancer biomarkers useful in the clinical practice?. Tumor Biology 40:9, pages 101042831879925.
Crossref
Crossref
Junjie Tony Hua, Musaddeque Ahmed, Haiyang Guo, Yuzhe Zhang, Sujun Chen, Fraser Soares, Jennifer Lu, Stanley Zhou, Miranda Wang, Hui Li, Nicholas B. Larson, Shannon K. McDonnell, Parasvi S. Patel, Yi Liang, Cindy Q. Yao, Theodorus van der Kwast, Mathieu Lupien, Felix Y. Feng, Amina Zoubeidi, Ming-Sound Tsao, Stephen N. Thibodeau, Paul C. Boutros & Housheng Hansen He. (2018) Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19. Cell 174:3, pages 564-575.e18.
Crossref
Crossref
L. Wang, S.M. Dehm, D.W. Hillman, H. Sicotte, W. Tan, M. Gormley, V. Bhargava, R. Jimenez, F. Xie, P. Yin, S. Qin, F. Quevedo, B.A. Costello, H.C. Pitot, T. Ho, A.H. Bryce, Z. Ye, Y. Li, P. Eiken, P.T. Vedell, P. Barman, B.P. McMenomy, T.D. Atwell, R.E. Carlson, M. Ellingson, B.W. Eckloff, R. Qin, F. Ou, S.N. Hart, H. Huang, J. Jen, E.D. Wieben, K.R. Kalari, R.M. Weinshilboum, L. Wang & M. Kohli. (2018) A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone. Annals of Oncology 29:2, pages 352-360.
Crossref
Crossref
Adam J. Gadzinski & Matthew R. Cooperberg. 2018. Genitourinary Cancers. Genitourinary Cancers
55
86
.
Joshua I. Warrick & Scott A. Tomlins. 2018. Precision Molecular Pathology of Prostate Cancer. Precision Molecular Pathology of Prostate Cancer
503
522
.
Chad A. Reichard & Eric A. Klein. 2018. Active Surveillance for Localized Prostate Cancer. Active Surveillance for Localized Prostate Cancer
121
133
.
Derya Tilki, Thenappan Chandrasekar, Alexander Kretschmer & Felix K. Chun. 2018. Urologic Oncology. Urologic Oncology
1
16
.
Alexander Kretschmer & Derya Tilki. (2017) Biomarkers in prostate cancer – Current clinical utility and future perspectives. Critical Reviews in Oncology/Hematology 120, pages 180-193.
Crossref
Crossref
Stefan Steurer, Sebastian Dwertmann Rico, Ronald Simon, Sarah Minner, Maria Christina Tsourlakis, Till Krech, Christina Koop, Markus Graefen, Hans Heinzer, Meike Adam, Hartwig Huland, Thorsten Schlomm, Guido Sauter & Agron Lumiani. (2017) High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. BJU International 120:3, pages 365-376.
Crossref
Crossref
Stacy Loeb & Ashley E. Ross. (2017) Genomic testing for localized prostate cancer. Current Opinion in Urology 27:5, pages 495-499.
Crossref
Crossref
Irene V. Bijnsdorp, Martin E. van Royen, Gerald W. Verhaegh & Elena S. Martens-Uzunova. (2017) The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. Molecular Diagnosis & Therapy 21:4, pages 385-400.
Crossref
Crossref
Michael S. Leapman & Peter R. Carroll. (2017) Risk Stratification of Newly Diagnosed Prostate Cancer with Genomic Platforms. Urology Practice 4:4, pages 322-328.
Crossref
Crossref
Kathryn L. Pellegrini, Martin G. Sanda, Dattatraya Patil, Qi Long, María Santiago-Jiménez, Mandeep Takhar, Nicholas Erho, Kasra Yousefi, Elai Davicioni, Eric A. Klein, Robert B. Jenkins, R. Jeffrey Karnes & Carlos S. Moreno. (2017) Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU International 119:6, pages 961-967.
Crossref
Crossref
Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa & Chikara Ohyama. (2016) Recent progress and perspectives on prostate cancer biomarkers. International Journal of Clinical Oncology 22:2, pages 214-221.
Crossref
Crossref
Cristiana Pistol Tanase, Elena Codrici, Ionela Daniela Popescu, Simona Mihai, Ana-Maria Enciu, Laura Georgiana Necula, Adrian Preda, Gener Ismail & Radu Albulescu. (2017) Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget 8:11, pages 18497-18512.
Crossref
Crossref
Samuel C. Haywood, Andrew J. Stephenson & Eric A. Klein. (2017) Gene Expression Testing as a Predictor of Adverse Pathology after Radical Prostatectomy: Implications for Choosing Patients for Active Surveillance. Urology Practice 4:2, pages 140-148.
Crossref
Crossref
Michael S. Leapman & Peter R. Carroll. (2017) What is the best way not to treat prostate cancer?. Urologic Oncology: Seminars and Original Investigations 35:2, pages 42-50.
Crossref
Crossref
Yu Yin, Qingfu Zhang, Hong Zhang, Yiping He & Jiaoti Huang. (2017) Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk. Clinical Cancer Research 23:1, pages 6-8.
Crossref
Crossref
J. Scott Ferguson, Ryan Van Wert, Yoonha Choi, Michael J. Rosenbluth, Kate Porta Smith, Jing Huang & Avrum Spira. (2016) Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Christina S. Fjeldbo, Cathinka H. Julin, Malin Lando, Malin F. Forsberg, Eva-Katrine Aarnes, Jan Alsner, Gunnar B. Kristensen, Eirik Malinen & Heidi Lyng. (2016) Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. Clinical Cancer Research 22:16, pages 4067-4076.
Crossref
Crossref
Claire Tonry, Emma Leacy, Cinzia Raso, Stephen Finn, John Armstrong & Stephen Pennington. (2016) The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics 6:3, pages 27.
Crossref
Crossref
Jeffrey J. TosoianStacy LoebJonathan I. EpsteinBaris TurkbeyPeter L. ChoykeEdward M. Schaeffer. (2016) Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book:36, pages e235-e245.
Crossref
Crossref
Michael S. Leapman, Hao G. Nguyen & Matthew R. Cooperberg. (2016) Clinical Utility of Biomarkers in Localized Prostate Cancer. Current Oncology Reports 18:5.
Crossref
Crossref
Jeffrey J. Tosoian, H. Ballentine Carter, Abbey Lepor & Stacy Loeb. (2016) Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nature Reviews Urology 13:4, pages 205-215.
Crossref
Crossref
Pranav Sharma, Kamran Zargar-Shoshtari & Julio M Pow-Sang. (2016) Biomarkers for prostate cancer: present challenges and future opportunities. Future Science OA 2:1.
Crossref
Crossref
A E Ross, A V D'Amico & S J Freedland. (2015) Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer and Prostatic Diseases 19:1, pages 1-6.
Crossref
Crossref
Neal D. Shore, Naveen Kella, Brian Moran, Judd Boczko, Fernando J. Bianco, E. David Crawford, Thaylon Davis, Kirstin M. Roundy, Kristen Rushton, Charles Grier, Rajesh Kaldate, Michael K. Brawer & Mark L. Gonzalgo. (2016) Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. Journal of Urology 195:3, pages 612-618.
Crossref
Crossref
Itay A. SternbergIan VelaPeter T. Scardino. (2016) Molecular Profiles of Prostate Cancer: To Treat or Not to Treat. Annual Review of Medicine 67:1, pages 119-135.
Crossref
Crossref
Dario Pugliese, Giuseppe Palermo, Angelo Totaro, Pier Francesco Bassi & Francesco Pinto. (2016) Clinical, Pathological and Molecular Prognostic Factors in Prostate Cancer Decision-Making Process. Urologia Journal 83:1, pages 14-20.
Crossref
Crossref
Mariangela Mancini, Michele Zazzara & Filiberto Zattoni. (2016) Stem Cells, Biomarkers and Genetic Profiling: Approaching Future Challenges in Urology. Urologia Journal 83:1, pages 4-13.
Crossref
Crossref
Pierre-Olivier GaudreauJohn StaggDenis SoulièresFred Saad. (2016) The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomarkers in Cancer 8s2, pages BIC.S31802.
Crossref
Crossref
Neal D. Shore & Karen Ventii. 2016. The Prostate Cancer Dilemma. The Prostate Cancer Dilemma
127
137
.
Joshua A. Roth, Scott D. Ramsey & Josh J. Carlson. (2015) Cost‐Effectiveness of a Biopsy‐Based 8‐Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. The Oncologist 20:12, pages 1355-1364.
Crossref
Crossref
Peter J. Boström, Anders S. Bjartell, James W.F. Catto, Scott E. Eggener, Hans Lilja, Stacy Loeb, Jack Schalken, Thorsten Schlomm & Matthew R. Cooperberg. (2015) Genomic Predictors of Outcome in Prostate Cancer. European Urology 68:6, pages 1033-1044.
Crossref
Crossref
Martin Spahn, Silvan Boxler, Steven Joniau, Marco Moschini, Bertrand Tombal & R. Jeffrey Karnes. (2015) What is the Need for Prostatic Biomarkers in Prostate Cancer Management?. Current Urology Reports 16:10.
Crossref
Crossref
Chad A. Reichard, Andrew J. Stephenson & Eric A. Klein. (2015) Applying precision medicine to the active surveillance of prostate cancer. Cancer 121:19, pages 3403-3411.
Crossref
Crossref
Peter Blume-Jensen, David M. Berman, David L. Rimm, Michail Shipitsin, Mathew Putzi, Thomas P. Nifong, Clayton Small, Sibgat Choudhury, Teresa Capela, Louis Coupal, Christina Ernst, Aeron Hurley, Alex Kaprelyants, Hua Chang, Eldar Giladi, Julie Nardone, James Dunyak, Massimo Loda, Eric A. Klein, Cristina Magi-Galluzzi, Mathieu Latour, Jonathan I. Epstein, Philip Kantoff & Fred Saad. (2015)
Development and Clinical Validation of an
In Situ
Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
. Clinical Cancer Research 21:11, pages 2591-2600.
Crossref
Crossref
Andrew S. Behesnilian & Robert E. Reiter. (2015) Risk stratification of prostate cancer in the modern era. Current Opinion in Urology 25:3, pages 246-251.
Crossref
Crossref
Maryam Esfahani, Negar Ataei & Mojtaba Panjehpour. (2015) Biomarkers for Evaluation of Prostate Cancer Prognosis. Asian Pacific Journal of Cancer Prevention 16:7, pages 2601-2611.
Crossref
Crossref
Said Abdallah Al-Mamari & Salim Said Al-Busaidy. 2015. Urological Cancer Management. Urological Cancer Management
9
13
.